Australian Institute of Health and Welfare (2021) Alcohol and other drug treatment services in Australia: early insights., AIHW, Australian Government, accessed 01 December 2021
Australian Institute of Health and Welfare. (2021). Alcohol and other drug treatment services in Australia: early insights. Retrieved from https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/alcohol-other-drug-treatment-services-aus
Alcohol and other drug treatment services in Australia: early insights. Australian Institute of Health and Welfare, 14 April 2021, https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/alcohol-other-drug-treatment-services-aus
Australian Institute of Health and Welfare. Alcohol and other drug treatment services in Australia: early insights [Internet]. Canberra: Australian Institute of Health and Welfare, 2021 [cited 2021 Dec. 1]. Available from: https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/alcohol-other-drug-treatment-services-aus
Australian Institute of Health and Welfare (AIHW) 2021, Alcohol and other drug treatment services in Australia: early insights, viewed 1 December 2021, https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/alcohol-other-drug-treatment-services-aus
Get citations as an Endnote file:
PDF | 2Mb
Agencies included in the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS) are all publicly funded (at state, territory or Australian Government level) government and non-government agencies that provide one or more specialist alcohol and other drug treatment services, whether residential or non-residential. Acute care hospitals or psychiatric hospitals are also included if they have specialist alcohol and other drug units that provide treatment to non-admitted patients (for example, outpatient services), as are Indigenous or mental health services if they provide specialist alcohol and other drug treatment.
An individual who is assessed and/or accepted for treatment for their own or someone else’s alcohol or other drug problem from an in-scope agency and who is aged 10 or older at the start of the treatment episode.
A treatment episode is the period of contact between a client and a treatment provider where there are defined start (commencement) and end (cessation) dates. A treatment episode is considered closed where any of the following occurs: treatment is completed or has ceased; there has been no contact between the client and treatment provider for 3 months; or there is a change in the main treatment type, principal drug of concern or delivery setting.
Treatment episodes are excluded from the AODTS NMDS if they: are not closed in the relevant financial year; are for clients who are receiving pharmacotherapy and not receiving any other form of treatment that falls within the scope of the collection; include only activities relating to needle and syringe exchange; or are for a client aged under 10 years.
Treatment type refers to the type of activity used to treat the client’s alcohol or other drug problem. Main treatment type is the principal activity that is determined at assessment by the treatment provider to be necessary for the completion of the treatment plan for the client’s alcohol or other drug problem for their principal drug of concern. One main treatment type is reported for each treatment episode.
Assessment only, can only be reported as a main treatment type. In 2019–20, changes were made to categories under Main Treatment; the word ‘only’ was removed from support and case management and information and education. The removal of the word ‘only’ from support and case management and information and education, changed reporting rules for agencies; allowing agencies to be able to report and more accurately capture these items as an additional treatment in conjunction with a main treatment type.
The AODTS NMDS also collects data on a client's other treatment types; however, this variable is not included in these data visualisations.
Principal drug of concern is the main drug that the client stated led them to seek treatment from the AOD treatment agency. In this report, only clients seeking treatment for their own drug use are included in analyses of principal drug of concern. It is assumed that only substance users themselves can accurately report principal drug of concern; therefore, these data are not collected from those who seek support for someone else’s drug use. The AODTS NMDS also collects data on a client's additional drugs of concern, but this variable is not included in these data visualisations.
The reasons for a client ceasing to receive a treatment episode from an alcohol and other drug treatment service include:
The source from which the client was transferred or referred to alcohol and other drug treatment service.
The main physical setting in which the type of treatment that is the principal focus of a client's alcohol and other drug treatment episode is actually delivered to a client (irrespective of whether or not this is the same as the usual location of the service provider).
The number of agencies is not an accurate reﬂection of all in-scope AOD specialist treatment services in Australia, as some agencies fail to report data during a collection for various reasons. See the Alcohol and other drug treatment services NMDS, 2019–20 data quality statement for details.
In 2018–19, the AOD treatment agency counting methodology was revised to better reflect the number of unique AOD treatment service outlets. There is a level of agency duplication, due to agencies splitting out episode data that is related to the funding source for that program/service. Some agencies chose to split their data according to the funding source such as, state funded service episodes are reported to the relevant state or territory department and the Commonwealth funded service episodes are separated and reported to a peak body or directly to the AIHW, this has resulted in some services being counted as two separate agencies over time. The revision was applied to all time-series, with AOD service counts from 2015–16 to 2017–18 affected.
Data is based on client records with a valid Statistical Linkage Key (SLK-581).
Client data exists from the 2013–14 collection onwards.
The client data used in these visualisations is not imputed. Therefore, these numbers may diﬀer from what has been previously published.
Rates are crude rates based on the Australian estimated resident population as at 31 December of the reference year. Rates for previous years may differ to previously reported due to updated estimated resident populations.
Proportions are calculated based on overlapping unit record data sorted by state/territory. As clients can receive treatment in multiple states/territories within the same collection period, the number of clients for Australia is less than the summed number of clients for each state/territory. Therefore, the proportions by each state/territory may diﬀer from those reported elsewhere as they are calculated from the summed number of clients for each state/territory.
Rehabilitation, withdrawal management (detoxiﬁcation), and pharmacotherapy are not available for clients seeking treatment for someone else’s alcohol or other drug use.
The main treatment type of ‘other’ includes pharmacotherapy.
South Australia reports a high proportion of Assessment only treatment episodes due to legislated client assessments under the state’s Police Drug Diversion Initiative and child protection programs.
In 2019–20, code for additional treatment type 'Other' updated from code 5 to 88. Code 5 (support and case management) and 6 (information and education) were added for additional treatment type. Removal of the word ‘only’ from Code 5 (support and case management), and Code 6 (information and education) was applied in 2019-20. Removal of word 'only' allowed agencies to report and more accurately capture additional treatment types used in conjunction with these two treatment types.
The AODTS NMDS contains data on drugs of concern that are coded using the ABS’s Australian Standard Classification of Drugs of Concern (ASCDC) (ABS 2011). Pharmaceuticals were grouped using the following 10 drug categories and ASCDC codes:
1100, 1199, 1200, 1299, 1300–1304, 1306–1399
0005, 1000, 1400–1499
Other sedatives and hypnotics
2000, 2200–2299, 2300–2399, 2500–2599, 2900–2999
ABS 2011. Australian Standard Classification of Drugs of Concern, 2011. ABS cat. No. 1248.0. Canberra: ABS.
Man, N., et al., Trends in cocaine use, markets and harms in Australia, 2003–2019. Drug Alcohol Rev, 2021.
We'd love to know any feedback that you have about the AIHW website, its contents or reports.
The browser you are using to browse this website is outdated and some features may not display properly or be accessible to you. Please use a more recent browser for the best user experience.